
Brainsway (BWAY) Stock Forecast & Price Target
Brainsway (BWAY) Analyst Ratings
Bulls say
BrainsWay Ltd. has demonstrated robust growth indicators, with remaining performance obligations increasing by approximately 43% year-over-year to around $70 million, signaling strong demand for its Deep TMS systems. The company shipped 95 Deep TMS systems in the fourth quarter of 2025, marking a 27% year-over-year increase, which supports a modestly raised revenue forecast for 2026 from $65.6 million to $66.8 million, alongside a new revenue estimate of $81.2 million for 2027. Additionally, the recent FDA approval of the Neurolief Proliv™Rx device enhances the company's market positioning and intrinsic value, contributing to an overall positive outlook driven by sustained operational performance and growth prospects in the neurostimulation market.
Bears say
The negative outlook on BrainsWay's stock is primarily attributed to the risks associated with the slower-than-anticipated uptake of its Deep TMS systems, which could hinder revenue growth. Additionally, the company's challenges in expanding reimbursement and market access, together with the potential inability to advance into new therapeutic indications, further contribute to concerns about its long-term financial viability. Lastly, the possibility of long-term dilution adds another layer of risk for investors, impacting their confidence in the stock's performance.
This aggregate rating is based on analysts' research of Brainsway and is not a guaranteed prediction by Public.com or investment advice.
Brainsway (BWAY) Analyst Forecast & Price Prediction
Start investing in Brainsway (BWAY)
Order type
Buy in
Order amount
Est. shares
0 shares